Profile data is unavailable for this security.
About the company
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
- Revenue in USD (TTM)11.79m
- Net income in USD-280.46m
- Incorporated2012
- Employees163.00
- LocationProthena Corporation PLC77 Sir John Rogerson's QuayBlock C, Grand Canal DocklandsDUBLIN D02 VK60IrelandIRL
- Phone+353 12362500
- Fax+353 19023510
- Websitehttps://www.prothena.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kyverna Therapeutics Inc | 0.00 | -160.99m | 415.32m | 129.00 | -- | 2.10 | -- | -- | -3.72 | -3.72 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -61.17 | -- | -69.77 | -- | -- | -- | -- | -- | -- | -- | 0.0013 | -- | -- | -- | -111.17 | -- | -- | -- |
| Zura Bio Ltd | 0.00 | -62.52m | 417.77m | 30.00 | -- | 3.41 | -- | -- | -0.6686 | -0.6686 | 0.00 | 1.66 | 0.00 | -- | -- | 0.00 | -39.10 | -- | -49.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.45 | -- | -- | -- |
| Vanda Pharmaceuticals Inc. | 212.07m | -84.20m | 427.27m | 368.00 | -- | 0.9169 | -- | 2.01 | -1.43 | -1.43 | 3.61 | 7.89 | 0.3403 | 6.46 | 4.55 | 576,288.10 | -13.51 | 1.56 | -16.20 | 1.80 | 94.44 | 91.45 | -39.70 | 3.99 | 3.10 | -- | 0.011 | 0.00 | 3.18 | -2.64 | -853.29 | -- | -13.62 | -- |
| Tectonic Therapeutic Inc | 0.00 | -67.30m | 427.85m | 51.00 | -- | 1.60 | -- | -- | -3.85 | -3.85 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -30.20 | -- | -32.12 | -- | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -35.40 | -- | -- | -- |
| 4D Molecular Therapeutics Inc | 120.00k | -209.18m | 427.96m | 227.00 | -- | 1.06 | -- | 3,566.30 | -3.74 | -3.74 | 0.0022 | 7.89 | 0.0002 | -- | -- | 528.63 | -40.70 | -32.02 | -43.51 | -33.96 | -- | -- | -174,314.20 | -895.24 | -- | -- | 0.00 | -- | -99.82 | -64.94 | -59.53 | -- | 3.40 | -- |
| Vor Biopharma Inc | 0.00 | -2.45bn | 431.95m | 159.00 | -- | -- | -- | -- | -386.85 | -386.85 | 0.00 | -246.54 | 0.00 | -- | -- | 0.00 | -1,676.47 | -49.21 | -1,891.22 | -52.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8052 | -- | -21.08 | -- |
| Ocugen Inc | 5.37m | -64.02m | 436.09m | 95.00 | -- | 117.57 | -- | 81.21 | -0.2167 | -0.2167 | 0.0182 | 0.0113 | 0.0899 | -- | -- | 56,526.32 | -107.12 | -79.82 | -153.51 | -95.76 | -- | -- | -1,192.18 | -2,251.08 | -- | -19.41 | 0.8894 | -- | -32.82 | -- | 14.31 | -- | 158.28 | -- |
| Lenz Therapeutics Inc | 17.50m | -58.88m | 437.12m | 42.00 | -- | -- | -- | 24.98 | -2.11 | -2.11 | 0.6268 | -- | -- | -- | -- | 416,666.70 | -- | -39.77 | -- | -42.56 | -- | -- | -336.47 | -- | -- | -- | -- | -- | -- | -- | 60.07 | -- | -- | -- |
| Alto Neuroscience Inc | 0.00 | -62.26m | 438.35m | 76.00 | -- | 3.44 | -- | -- | -2.31 | -2.31 | 0.00 | 4.11 | 0.00 | -- | -- | 0.00 | -36.77 | -- | -39.46 | -- | -- | -- | -- | -- | -- | -- | 0.1675 | -- | -- | -- | -69.21 | -- | -- | -- |
| Prothena Corporation PLC | 11.79m | -280.46m | 449.48m | 163.00 | -- | 1.52 | -- | 38.14 | -5.21 | -5.21 | 0.219 | 5.48 | 0.0249 | -- | -- | 72,306.75 | -59.18 | -14.95 | -65.99 | -16.06 | -- | -- | -2,379.59 | -89.33 | -- | -- | 0.00 | -- | 47.92 | 178.00 | 16.81 | -- | -11.70 | -- |
| Organogenesis Holdings Inc | 465.22m | -13.39m | 470.84m | 869.00 | -- | 1.85 | 98.34 | 1.01 | -0.1108 | -0.1108 | 3.62 | 3.04 | 0.9731 | 3.56 | 3.45 | 535,348.70 | 0.2102 | 6.65 | 0.2549 | 8.18 | 74.49 | 75.66 | 0.216 | 6.14 | 2.88 | -- | 0.0085 | 0.00 | 11.29 | 13.06 | -118.95 | -- | 9.98 | -- |
| Ginkgo Bioworks Holdings Inc | 180.61m | -339.55m | 479.15m | 834.00 | -- | 0.8448 | -- | 2.65 | -6.22 | -6.22 | 3.31 | 9.85 | 0.1353 | -- | 7.80 | 216,554.00 | -25.43 | -68.97 | -27.83 | -75.53 | 72.71 | 66.73 | -188.00 | -409.12 | -- | -- | 0.00 | -- | -9.71 | 33.18 | 38.73 | -- | 23.00 | -- |
| Lyell Immunopharma Inc | 41.00k | -325.66m | 480.96m | 300.00 | -- | 1.33 | -- | 11,730.81 | -22.26 | -22.26 | 0.0027 | 17.06 | 0.00008 | -- | -- | 136.67 | -63.41 | -28.62 | -67.72 | -30.08 | -- | -- | -794,292.70 | -1,176.84 | -- | -- | 0.00 | -- | -53.08 | -37.83 | -46.18 | -- | 14.67 | -- |
| ADC Therapeutics SA | 75.21m | -166.94m | 484.36m | 263.00 | -- | -- | -- | 6.44 | -1.51 | -1.51 | 0.6852 | -2.11 | 0.2355 | 0.3207 | 3.20 | 285,965.80 | -52.26 | -45.95 | -65.58 | -53.58 | 92.73 | -- | -221.97 | -263.96 | 4.34 | -2.91 | 2.10 | -- | 1.84 | 97.79 | 34.25 | -- | -16.59 | -- |
| Verastem Inc | 13.38m | -241.11m | 484.53m | 78.00 | -- | -- | -- | 36.22 | -4.02 | -4.02 | 0.2209 | -0.2326 | 0.0882 | -- | 3.76 | 171,525.60 | -159.03 | -68.26 | -233.92 | -83.33 | 85.14 | -- | -1,802.12 | -417.53 | 2.55 | -- | 1.21 | -- | -- | -10.54 | -49.53 | -- | 31.95 | -- |
Data as of Feb 06 2026. Currency figures normalised to Prothena Corporation PLC's reporting currency: US Dollar USD
41.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 7.90m | 14.68% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 2.97m | 5.52% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.88m | 3.50% |
| Armistice Capital LLCas of 30 Sep 2025 | 1.82m | 3.39% |
| Rubric Capital Management LPas of 30 Sep 2025 | 1.54m | 2.86% |
| Adar1 Capital Management LLCas of 30 Sep 2025 | 1.47m | 2.73% |
| Palo Alto Investors LPas of 30 Sep 2025 | 1.32m | 2.46% |
| D. E. Shaw & Co. LPas of 30 Sep 2025 | 1.32m | 2.44% |
| Acadian Asset Management LLCas of 30 Sep 2025 | 1.24m | 2.30% |
| Geode Capital Management LLCas of 30 Sep 2025 | 1.02m | 1.89% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
